Smith+Nephew Finally Taps Into Market Upside
The company grew in the high-single-digits in the third quarter of 2023, driven by market recovery and improving operational performance....
The company grew in the high-single-digits in the third quarter of 2023, driven by market recovery and improving operational performance....
The company grew in the mid-single-digits for the third quarter of 2023, driven by new products and better-than-expected orthobiologics sales....
The company grew in the high-single-digits in the third quarter of 2023, driven by new products and robotic procedures....
The company's 3Q23 orthopedic sales declined by nearly 10% due to continued competitive pressure and an exit from the Chinese...
The company's orthopedic sales grew in the mid-single-digits for the third quarter of 2023 and displayed newfound resiliency. ...
The company grew in the low single digits in 3Q23 and announced a two-year restructuring of its orthopedics business....
The company grew more than 20% in the first half of 2023 primarily as a result of volume won during...
The company grew in the high single digits in the first half of 2023 as it overcome supply challenges domestically...
The company grew in the high-single-digits in FY1Q24 driven by sales and pull-through from its Aible digital ecosystem....
The company grew in the mid-teens for the first half of 2023, driven by strength across its trauma portfolio and...
As a guest member you get access to more articles and webinars every month.
We’ll send a recovery link to your email.
Return to Homepage